Affiliation:
1. School of Nursing, University of Mississippi Medical Center, Jackson, MS, USA
2. Mississippi Centre for Evidence Based Practice: A JBI Centre of Excellence, Jackson, MS, USA
Abstract
Objective:The objective of this review is to synthesize the best evidence available to determine the prevalence and incidence of anal cancer in HIV-positive men.Introduction:Worldwide, an estimated 50,685 people were diagnosed with anal cancer in 2020 and an estimated 19,293 people died from the disease during the same year. From 2001 to 2015, the overall incidence of anal cancer increased by 2.7% per year, while mortality jumped by 3.1% each year. Evidence has shown that anal intraepithelial neoplasia can progress to cancer over time, particularly within the immunocompromised population.Inclusion criteria:This review will consider studies conducted in any setting, in any geographical location that report on the prevalence and incidence of adult males aged 18 years or older from any racial or ethnic background who are HIV positive and diagnosed with any type of anal cancer. Participants will be included regardless of stage of anal cancer, type of cancer treatment used, or length of time diagnosed.Methods:CINAHL, MEDLINE, Embase, LBGTQ+ Source (EBSCO), Web of Science Core Collection, MedNar, WorldWideScience, and ProQuest Dissertations and Theses databases will be searched from 1990 till the present. Analytical and descriptive observational studies will be included and critically appraised by 2 independent reviewers. Data will be extracted using JBI standardized data extraction tools. If sufficient data are available, a meta-analysis will be conducted; otherwise, the findings will be presented in narrative format, including tables and figures to aid in data presentation.Review registration:PROSPERO CRD42022327933
Publisher
Ovid Technologies (Wolters Kluwer Health)